紫杉醇脂质体胸腔内给药治疗恶性胸腔积液的临床观察  

Clinical Observation of Paclitax Liposome Intrapleural Administration in the Treatment of Malignant Pleural Effusion

作　　者：朱长庚[1] 

机构地区：[1]郑州市第六人民医院胸外科,郑州450015

出　　处：《中国医药导刊》2014年第1期93-94,共2页Chinese Journal of Medicinal Guide

摘　　要：目的：对恶性胸腔积液患者行紫杉醇脂质体胸腔内给药的临床治疗效果展开观察与探讨。方法：取2010年5月-2013年2月期间在院治疗的恶性胸腔积液患者51例为研究对象，其中26例患者行紫杉醇脂质体治疗，设为观察组；剩余25例患者行顺铂治疗，设为参照组。两组患者给药方式均为胸腔内给药。对两组患者临床治疗效果展开评估，并观察其不良反应。结果：与参照组相比，观察组患者治疗总有效率明显更高，组间差异具有统计学意义（P〈0.05），且观察组患者未出现过敏反应，伴有轻微毒副反应。结论：恶性胸腔积液患者行紫杉醇脂质体胸腔内给药治疗后疗效确切且安全，应在临床上广泛应用。Objective：Expansion of clinical therapeutic effect in patients with malignant pleural effusion of paclitaxel liposome intrapleural administration.Methods：From 2010 May-2013 year in February during the malignant pleural effusion were 51 cases as the research object, of which 26 patients received paclitaxel liposome treatment, for the observation group;the remaining 25 patients were treated with cisplatin treatment, as the reference group. Two groups of patients were administered intrapleural administration. A review of the clinical therapeutic effect of two groups of patients, and to observe the adverse reaction.Results：Compared with the control group, patients in the observation group the total effective rate was significantly higher, the differences between groups was statistically significant （P〈0.05）, and the patients in the observation group did not appear allergic reaction, with mild side reaction.Conclusion：Patients with malignant pleural effusion of paclitaxel liposome intrapleural administration of treatment efficacy and safety, should be widely used in clinical.

关 键 词：恶性胸腔积液 顺铂 紫杉醇脂质体 

分 类 号：R730.5[医药卫生—肿瘤]